Assessing the efficacy and safety of pitavastatin compared to atorvastatin in dyslipidemic patients: a double blind randomized controlled trial
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20161530Keywords:
Dyslipidemia, Pitavastatin, AtorvastatinAbstract
Background: Statins are the first choice in the treatment of dyslipidemia, commonly atorvastatin. Pitavastatin is a newer statin with more potency, less drug interactions and many added advantages considering the longevity of treatment required for dyslipidemia. The objective of this study was to evaluate the efficacy and safety of pitavastatin versus atorvastatin in dyslipidemic patients associated with hypertension, diabetes and/or coronary artery disease.
Methods: A prospective, comparative, randomized, controlled, double blind, clinical trial was designed. Total 100 eligible subjects were randomised into 1:1 ratio to receive pitavastatin 4 mg once daily and atorvastatin 20 mg once daily for period of 8 weeks. Evaluation was scheduled at 4 week and 8 week. The efficacy assessment included percentage change from baseline in various lipid parameters like low density lipoprotein cholesterol (LDLC), total cholesterol (TC), high density lipoprotein cholesterol (HDLC), triglycerides (TG), and LDLC/HDLC ratio.
Results: Analysis of data showed a significant improvement in all lipid parameters within both therapeutic groups. The difference in LDLC, TC and TG levels was not statistically significant between the two treatment groups after 8 weeks of therapy. However, significant improvement was seen in HDLC and LDLC/HDLC ratio with pitavastatin as compared to atorvastatin at the end of the study. Both were well tolerated.
Conclusions: With better HDLC levels, in addition to comparable efficacy and good tolerability of pitavastatin, as compared to atorvastatin, could be considered as good alternative for treatment of dyslipidemia.
References
Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed 2 November 2012.
Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Cholesterol treatment trialists' (CTT) collaborators, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25.
American diabetes association. Standards of medical care in diabetes. Diabetes Care. 2010;33(1):11-61.
Fruchart JC. Peroxisome proliferator-activated receptor alpha activation and high-density lipoprotein metabolism. Am J Cardiol. 2001;88(12):24-9.
Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 12th ed. New York. McGraw-Hill Publications; 2011:877-908.
World health organisation. Cardiovascular diseases (CVDs). Available at URL: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed 31 October 2012.
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32(14):1769-818.
Libby P. The pathogenesis, prevention, and treatment of atherosclerosis. In: Longo DL, Fausi AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine.18th ed. New York. McGraw-Hill Publications; 2012:1983-91.
Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59(2):239-52.
Prescribing information of pitavastatin. Available at URLhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2009/02236 s000lbl.pdf. Accessed 2 November 2012.
Duggan ST. Pitavastatin: a review of its use in the management of hypercholesterolemia or mixed dyslipidaemia. Drugs. 2012;72(4):565-84.
Suzuki M, Iwasaki H, Fujikawa Y, Kitahara M, Sakashita M, Sakoda R. Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg Med Chem. 2001;9(10):2727-43.
Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl- coenzyme A reductase. Arzneimittelforschung. 1997;47(8):904-9.
Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138-44.
Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins achilles heel? Curr Med Res Opin. 2011;27(8):1551-62.
Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60(5):494-7.
Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag. 2009;5:921-36.
Chong PH, Seeger JD. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors pharmacotherapy. 1997;17(6):1157-77.
Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf. 2010;9(4):667-74.
Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin. Cochrane Database of Systematic Reviews. Cochrane Database Syst Rev. 2015;3:CD008226.
Phatak H, Wentworth C, Sazonov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis. 2009;202(1):225-33.
Ferrières J, Gousse ET, Fabry C, Hermans MP; French CEPHEUS investigators. Assessment of lipid-lowering treatment in France-the CEPHEUS study. Arch Cardiovasc Dis. 2008;101(9):557-63.
Ruiz FJG, Ibáñez AM, Jiménez FP, Pintó X, Nocea G, Ahumada C, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics. 2004;22(3):1-12.
Hermans MP, Cabezas MC, Strandberg T, Ferrières J, Feely J, Elisaf M, et al. Centralized Pan-European survey on the under treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries (CEPHEUS). Curr Med Res Opin. 2010;26(2):445-54.
Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823-8.
Lipid research clinics program. The lipid research clinics coronary primary prevention trial results. I: Reduction in the incidence of coronary heart disease. JAMA. 1984;251(3):351-64.
Lipid research clinics program. The lipid research clinics coronary primary prevention trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365-74.
Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323(16):1112-9.
Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322(24):1700-7.
Toth PP. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs. 2010;70(11):1363-79.
Davidson MH, Toth PP. Comparative effects of lipid lowering therapies. Prog Cardiovasc Dis. 2004;47(2):73-104.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22.
Scandinavian simvastatin survival study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383-9.
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease; a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-6.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with Atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-58.
Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab. 2011;13(11):1047-55.
Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin. 2009;25(11):2755-64.
Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther. 2011;28(9):811-23.
Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4(3):291-302.
Kawashiri MA, Nohara A, Tada H, Mori M, Tsuchida M, Katsuda S, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther. 2008;83(5):731-9.
Nawrocki JW, Weiss SR, Davidson HM, Sprecher DL, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new hmg-Coa reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678.
Schrott H, Fereshetian AG, Knopp RH, Bays H, Jones PH, Littlejohn TW, et al. A multicenter, placebo-controlled, dose-ranging study of atorvastatin. J Cardiovasc Pharmacol Ther. 1998;3(2):119-24.
Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-7.
Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001;111(3):185-91.
Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T, et al; Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. Journal of Cardiology. 2013;62:87-94.
